CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04603495
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:48.198087+00:00
Published At: 2024-10-28T00:00:00+00:00
Record Updated At: 2025-12-17
Results Posted At: 2024-10-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Myelofibrosis", "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-17"
protocolSection.identificationModule.nctId: "NCT04603495"
protocolSection.identificationModule.officialTitle: "A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-10-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.